{"id":"W3214338991","doi":"10.1182/blood-2021-147812","title":"CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University","funders":"","keywords":"Bortezomib; Cereblon; Dexamethasone; Medicine; Lenalidomide; Multiple myeloma; Refractory (planetary science); Internal medicine; Pharmacology; Oncology; Ubiquitin ligase; Chemistry; Biology; Ubiquitin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004721183,0.0006595822,0.0008075998,0.0002694011,0.0001778708,0.0006039266,0.0004479249,0.0004598333,0.002524967],"category_scores_gemma":[0.0003374104,0.0002910297,0.0005642884,0.000335022,0.0003388862,0.0003587927,0.0002243879,0.001383774,0.0007664436],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005719422,"about_ca_system_score_gemma":0.0006109655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009271711,"about_ca_topic_score_gemma":0.002992968,"domain_scores_codex":[0.9998202,0.00006387031,0.00001306036,0.00003391707,0.00003131991,0.00003763493],"domain_scores_gemma":[0.9998125,0.00002221429,0.0000434877,0.00001365656,0.00001349977,0.00009468786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3014019,0.02890867,0.02677756,0.001660263,0.001544862,0.001072011,0.0004237142,0.004540379,0.3117721,0.0003427794,0.0136552,0.3079005],"study_design_scores_gemma":[0.2620946,0.5804271,0.07285943,0.0001061136,0.001568941,0.003490274,0.0001682538,0.003162669,0.05297936,0.000235316,0.02282412,0.00008388941],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895797,0.00538101,0.0003814327,0.0004377867,0.00006194249,0.000519085,0.001129632,0.0001450681,0.002364321],"genre_scores_gemma":[0.9914525,0.002893816,0.001059397,0.0004076468,0.0001015181,0.0003712208,0.002065339,0.000025804,0.001622756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002524967,"threshold_uncertainty_score":0.008446872,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02371270208355063,"score_gpt":0.2703067045698111,"score_spread":0.2465940024862605,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}